Zongertinib Receives Breakthrough Therapy Designation for Patients With HER2 Non-Small Cell Lung Cancer

Zongertinib Receives Breakthrough Therapy Designation for Patients With HER2 Non-Small Cell Lung Cancer

Zongertinib promises significant advancements in patient care.

FDA Grants Breakthrough Therapy Designation to HERNEXEOS for First-Line Treatment of HER2-Mutant Advanced NSCLC

The U.S. Food and Drug Administration (FDA) has granted […] The post FDA Grants Breakthrough Therapy Designation to HERNEXEOS for First-Line Treatment of HER2-Mutant Advanced NSCLC first appeared on GeneOnline News. The post FDA Grants Breakthrough Therapy Designation to HERNEXEOS for First-Line Treatment of HER2-Mutant Advanced NSCLC appeared first on GeneOnline News.

FDA Grants Breakthrough Therapy Designation to Zongertinib Tablets in NSCLC

Results from the Beamion-LUNG 1 trial showed an ORR of 75% for patients with HER2+ NSCLC treated with zongertinib.

FDA Grants BTD to Zongertinib, Marks New Frontier for HER2+ NSCLC

Zongertinib receives FDA breakthrough therapy designation for treating HER2-mutant non-small cell lung cancer, promising new hope for patients.